Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Vermont Tech Scene.
Press releases published on September 4, 2025
U.S. Clean Energy Market Projected to Reach $198 Billion by 2033 Driven by Record Renewable Deployments & Advancing Technologies
GlobeNewswire
·
September 4, 2025
PALM BEACH, Fla., Sept. 04, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - A recent report from a Clean Energy industry insider said that: “The U.S. clean energy market is thriving, driven by record renewable deployments and advancing …
SIOS Technology Named Among the Best Places to Work in South Carolina for the Sixth Consecutive Year
GlobeNewswire
·
September 4, 2025
SAN MATEO, Calif. and COLUMBIA, S.C., Sept. 04, 2025 (GLOBE NEWSWIRE) -- SIOS Technology Corp., a leading provider of application high availability (HA) and disaster recovery (DR) solutions, today announced that it has been named the 2025 Best Places to …
Clene Presents Preclinical Data Supporting CNM-Au8® for the Treatment of Parkinson’s Disease
GlobeNewswire
·
September 4, 2025
Novel human preclinical neuronal model for Parkinson’s disease demonstrated CNM-Au8’s ability to improve mitochondrial health, restore cellular metabolism, reduce inflammation, and normalize dysregulated gene expression in both familial and sporadic …
Profusa Adds Head of Vascular Surgery Department at AZ Sint Blasius Hospital, Belgium to Growing Customer Base
GlobeNewswire
·
September 4, 2025
Internationally recognized vascular surgeon, Dr. Koen Deloose provides patient access to latest innovative treatments and personalized care BERKELEY, Calif, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a …
CytoDyn Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire
·
September 4, 2025
VANCOUVER, Washington, Sept. 04, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage biotechnology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with …
Dr. Vuong Trieu, Developer of Novel Oncology and Immunotherapy Assets, Leads Oncotelic Therapeutics’ Commitment to Innovation, Life-Saving Therapies
GlobeNewswire
·
September 4, 2025
Dr. Trieu’s prolific career includes multibillion-dollar drug discoveries targeting cancers of the breast, pancreas and non-small cell lung cancer, among others Oncotelic’s robust portfolio and clinical pipeline is supported by the innovations and …
Vivani Medical Provides Update on Clinical Development Plans for NPM-139 Semaglutide Implant for Chronic Weight Management
GlobeNewswire
·
September 4, 2025
NPM-139 has potential to provide Wegovy®-level efficacy with once or twice-yearly administration First-in-human Phase 1 study is expected to initiate in the first half of 2026, pending regulatory clearance Preparations for dose-ranging Phase 2 study of NPM …
Lexicon Pharmaceuticals to Present New Preclinical Data on Pilavapadin in Chemotherapy-Induced Pain and Multiple Sclerosis Pain at NeuPSIG 2025
GlobeNewswire
·
September 4, 2025
THE WOODLANDS, Texas, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the Company will present new data demonstrating the reduction of neuropathic pain by pilavapadin in preclinical models of …
SEALSQ Accelerates Post-Quantum Readiness with Next-Generation TPMs Ahead of 2027 U.S. Government Deadline
GlobeNewswire
·
September 4, 2025
Geneva, Switzerland, Sept. 04, 2025 (GLOBE NEWSWIRE) -- SEALSQ Corp (NASDAQ: LAES) ("SEALSQ" or "Company"), a company that focuses on developing and selling Semiconductors, PKI, and Post-Quantum technology hardware and software products, today announced …
Bright Minds Biosciences Announces BMB‑201 Outperforms Sumatriptan in Validated Preclinical Vascular Headache Model
GlobeNewswire
·
September 4, 2025
NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (NASDAQ: DRUG) today announced compelling preclinical results for its investigational compound BMB‑201, in a validated isosorbide dinitrate (ISDN) rat model of vascular headache. …
ZenaTech to Highlight Progress on Drone as a Service and US Defense Business at Multiple Upcoming Investor Conferences
GlobeNewswire
·
September 4, 2025
VANCOUVER, British Columbia, Sept. 04, 2025 (GLOBE NEWSWIRE) -- ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) ("ZenaTech"), a business technology solution provider specializing in AI (Artificial Intelligence) drones, Drone as a Service (DaaS), …
Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at International Congress of Inborn Errors of Metabolism 2025
GlobeNewswire
·
September 4, 2025
Totality of data supports potential for isaralgagene civaparvovec as a one-time, durable treatment of the underlying pathology of Fabry disease to provide meaningful, multi-organ, clinical benefits above current standards of care STAAR study demonstrated …
IO Biotech Announces Participation in Upcoming Investor Conferences
GlobeNewswire
·
September 4, 2025
NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, announced today that members of its senior management team …
24/7 Market News: TEN Holdings Poised for High-Growth with SaaS Expansion and M&A Potential, Says All-Star
GlobeNewswire
·
September 4, 2025
DENVER, Sept. 04, 2025 (GLOBE NEWSWIRE) -- 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and corporate information, reports that Barry M. Sine, CFA, CMT, two-time Wall Street Journal All-Star …
Tharimmune Announces Upcoming Conference Presentations Highlighting Lead Asset TH104, A New Formulation Against Ultrapotent Opioids and Fentanyl
GlobeNewswire
·
September 4, 2025
RED BANK, N.J., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Tharimmune, Inc. (Nasdaq: THAR), a clinical-stage biotechnology company dedicated to developing innovative therapeutic candidates for inflammation, immunology, and critical unmet medical needs announced …
Arbe to Participate in Upcoming Investor Conferences
GlobeNewswire
·
September 4, 2025
Tel Aviv, Israel, September 4, 2025 - Arbe Robotics Ltd. (Nasdaq: ARBE) (TASE: ARBE), a global leader in perception radar solutions, today announced that members of Arbe’s management will be participating at the following investor conferences during …
U.S. EV Market Matures Despite Infrastructure Gaps and Consumer Hesitation
GlobeNewswire
·
September 4, 2025
HERE-SBD EV Index 2025 reveals U.S. entering early stages of large-scale EV deployment with gains across all four Index categories New consumer survey finds U.S. drivers most resistant to EV adoption compared to drivers in Europe, citing charging access as …
Connect Biopharma Announces Two Presentations at the European Respiratory Society (ERS) Congress 2025
GlobeNewswire
·
September 4, 2025
SAN DIEGO, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, …
PathAI Expands Clinical Leadership - Announcing Partnerships with Mindpeak, Stratipath, and Primaa
GlobeNewswire
·
September 4, 2025
BOSTON, Sept. 04, 2025 (GLOBE NEWSWIRE) -- PathAI, a global leader in AI-powered digital pathology solutions and the developer of the market-leading AISight Dx1 Image Management System (IMS), today announced new partnerships with three cutting-edge AI …
MBX Biosciences Doses First Participant in Phase 1 Trial of MBX 4291 for the Treatment of Obesity
GlobeNewswire
·
September 4, 2025
CARMEL, Ind., Sept. 04, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic …